- Home
- MOBX vs ANL Comparison
MOBX vs ANL Comparison
Compare MOBX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MOBX | ANL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Cayman Islands |
| Employees | 46 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 293.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MOBX | ANL |
|---|---|---|
| Price | $0.57 | $7.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 107.3M | 210.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.88 |
| 52 Week High | $1.44 | $12.09 |
Technical Indicators
Market Signals| Indicator | MOBX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 46.82 |
| Support Level | $0.22 | $7.21 |
| Resistance Level | $0.84 | $9.98 |
| Average True Range (ATR) | 0.21 | 1.07 |
| MACD | 0.00 | -0.31 |
| Stochastic Oscillator | 35.79 | 24.49 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.